<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7216760\results\search\testTrace\results.xml">
  <result pre="260,000 deaths, reflecting a âˆ¼6.8% case fatality rate. While the" exact="infection" post="fatality rate is currently unknown, and likely to be"/>
  <result pre="it is close to 1%, or approximately 10 times the" exact="infection" post="fatality rate of seasonal influenza (flu), which is fatal"/>
  <result pre="virus can mitigate this phase. In the third phase, the" exact="infection" post="rate curve will start to decrease until the disease"/>
  <result pre="limited innate immune response. Within the next few days the" exact="infection" post="starts in the upper airway and during this stage"/>
  <result pre="starts in the upper airway and during this stage the" exact="infection" post="can be detected by nasal swabs or sputum as"/>
  <result pre="infected patients will progress to develop a lower respiratory tract" exact="infection" post="leading to hypoxia, and lung damage. These patients are"/>
  <result pre="risk of death.14 The available data indicate that the viral" exact="infection" post="can produce an excessive immune reaction known as cytokine"/>
  <result pre="renal function as well as fertility. Surprisingly, the 2003 SARS-CoV" exact="infection" post="was shown to downregulate the expression of ACE2 in"/>
  <result pre="solely on the results of RNA molecular tests, large-scale antibody" exact="testing" post="should be expedited to identify individuals who have been"/>
  <result pre="current drug repurposing efforts. Camostat mesylate, approved in Japan for" exact="treatment" post="of pancreatic inflammation, has been shown to block TMPRSS2"/>
  <result pre="COVID-19 (NCT04330300). The availability of soluble recombinant hACE2 encouraged its" exact="testing" post="in two clinical trials; although one was terminated (NCT04287686)"/>
  <result pre="in interleukin signaling pathways. Another currently recruiting clinical trial is" exact="testing" post="quinolone, macrolide, and Î²-lactam antibiotics against COVID-19 (NCT02735707). Multiple"/>
  <result pre="of other Mpro inhibitors. One of the suggested agents for" exact="testing" post="is the previously reported Rhinovirus and SARS-CoV Mpro inhibitor"/>
  <result pre="Med.10.1056/NEJMoa2001282. KawaseM.; ShiratoK.; van der HoekL.; TaguchiF.; MatsuyamaS. (2012) Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
 </snippets>
</snippetsTree>
